News

Mr. Chi-Li Lee and Mr. Yin-Chi Tsai Successfully Reappointed by the Board of Directors as Chairman and General Manager

Yung Shin Pharmaceutical and the College of Pharmacy, National Taiwan University signed an MOU to collaborate on cultivating core biopharmaceutical talent.

Yung Shin Pharmaceutical partnered with Acer Medical to extend patient access of AI-assisted bone density abnormality screening.

Promoting VeriSee Dr AI device jointly by Acer Medical and Yung Shin Pharmaceutical to extend patient access.

Taiwan Liposome + Yung Shin Pharmaceutical National Team, Ampholipad (amphotericin B liposome) made an emergency medicine aid to India

As infectious diseases are becoming increasingly complex Yung Shin Pharmaceutical focuses on developing drugs for severe infections.

Congratulations on Yung Shin Pharmaceutical for receiving recognition!
Taichung Dajia Youth Industiral Park Plant 2 was awarded the first animal enzyme factory in Taiwan to pass the new FAMI-QS [Version 6.0] certification.

Yung Shinn Pharmaceutical invests in the clinical development of a new drug for acromegaly

Congratulations on Yung Shin Pharmaceutical for Eraflu (oseltamivir) being adopted by the Centers for Disease Control, Ministry of Health and Welfare.

Yung Shin Pharmaceutical earns TFDA's recognition for pharma quality upgrade.

Yungshin’s Cefaclor (Oral Suspension) Has Been Certified by FDA of the U.S. as a Standard Drug

Congratulations! Chairman of Yungshin Pharm Ind. Co. LTD Lee, Fang-Yu Was Awarded China Medical University Outstanding Alumni in Management Leadership and China Medical University College of Pharmacy Outstanding Alumni.

Yungshin’s Sterile Injection Plant Passed the Inspection of FDA of the U.S. without Deficiency

Yungshin’s Sterile Injection Plant Was Inspected by British MHRA (the Medicines and Healthcare Products Regulatory Agency)

Yungshin Took Over Active Pharmaceutical Ingredients (API) of JAC to Expand Generic Drugs in Japan

Yungshin Acquired 100% of Shares of Zoetis Biotech Manufacturing Limited to Improve Capacity for Animal Healthcare Products

J'FANCY BEAUT’E Press Conference

Recommendation of Authoritative Doctors in Aesthetic Medicine

The cardiovascular drug Clonidine Tablet was approved for marketing in Australia and Canada in November 2016 and March 2017, respectively.

In February, 2017, Yung Shin's hepatitis B medication, Entecavir Tablet, was approved for marketing by the Japanese Ministry of Health, Labour and Welfare.

Yung Shin Medical Museum Opened Officially to Promote Knowledge of Safe Medication

Yungshin’s Entecavir Tablet Was Approved by Ministry of Health, Labour and Welfare for Marketing in Japan in February 2017

Yungshin Actively Prepares Itself for International GMP Inspections to Drive Export